The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG;O uso de inibidores da enzima conversora de angiotensina e sua relação com eventos no pósoperatório de cirurgia de revascularização miocárdica

Brazilian Journal of Cardiovascular Surgery

Volumn 26, Issue 3, 2011, Pages 373-379

  Radaelli, Graciane ^d   Bodanese, Luiz Carlos ^a,b   Guaragna, João Carlos Vieira da Costa ^b   Borges, Anibal Pires ^b   Goldani, Marco Antonio ^b   Petracco, João Batista ^b   Piccoli, Jacqueline da Costa Escobar ^c   Albuquerque, Luciano Cabral ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

^d Santa Casa de Misericórdia de Porto Alegre   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81355164285     PISSN: 01027638     EISSN: 16789741     Source Type: Journal    
DOI: 10.5935/1678-9741.20110011     Document Type: Article

References (30)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
2. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-8.
3. Mill JG, Milanez MC, Busatto VCW, Moraes AC, Gomes MGS. Ativação da Enzima conversora de angiotensina no coração após infarto do miocárdio e suas repercussões no remodelamento ventricular. Arq Bras Cardiol. 1997;69(2):101-10.
4. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilatation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35(1):60-6.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-9.
6. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a highcholesterol diet. Br J Pharmacol. 1999;128(3):523-9.
7. rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Atherioscler Thromb Vasc Biol. 2002;22(8):1257-66.
8. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995;80(3):473-9.
9. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Pre-operative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol. 2008;3(5):1266-73.
10. Pigott DW, Nagle C, Allman K, Westaby S, Evans RD. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth. 1999;83(5):715-20.
11. Rady MY, Ryan T. The effects of preoperative therapy with angiotensin-converting enzyme inhibitors on clinical outcome after cardiovascular surgery. Chest. 1998;114(2):487-94.
12. Nascente RB, Guaragna JCVC, Franca AS, Spiandorello RM, Werutski G, Azevedo E, et al. Estabelecimento do ponto de corte da troponina I como marcador de infarto do miocárdio em cirurgia de revascularização miocárdica. Sci Med. 2005;15(3):142-7.
13. Cadore MP, Guaragna JCVC, Anacker JFA, Albuquerque LC, Bodanese LC, Piccoli JCE, et al. Proposição de um escore de risco cirúrgico em pacientes submetidos à cirurgia de revascularização miocárdica. Rev Bras Cir Cardiovasc. 2010;25(4):447-56.
14. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997;95(12):2643-51.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
16. Lazar HL. All coronary artery bypass graft surgery patients will benefit from angiotensin-converting enzyme inhibitors. Circulation. 2008;117(1):6-8.
17. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995;80(3):473-9.
18. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116(6):973-80.
19. Raja SG, Fida N. Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation? Interact Cardiovasc Thorac Surg. 2008;7(3):470-5.
20. Deakin CD, Dalrymple-Hay MJ, Jones P, Monro JL. Effects of angiotensin converting enzyme inhibition on systemic vascular resistance and vasoconstrictor requirements during hypothermic cardiopulmonary bypass. Eur J Cardiothorac Surg. 1998;13(5):546-50.
21. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19-32.
22. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol. 2008;3(5):1266-73.
23. Cittanova ML, Zubicki A, Savu C, Montalvan C, Nefaa N, Zaier K, et al. The chronic inhibition of angiotensin-converting enzyme impairs postoperative renal function. Anesth Analg. 2001;93(5):1111-5.
24. Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, et al; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117(1):24-31.
25. Kjøller-Hansen L, Steffensen R, Grande P. The Angiotensinconverting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000;35(4):881-8.
26. White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of pre-operative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg. 2007;31(5):817-20.
27. Echahidi N, Pibarot P, O'Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51(8):793-801.
28. Miceli A, Capoun R, Fino C, Narayan P, Bryan AJ, Angelini GD, et al. Outcome in patients undergoing coronary artery bypass grafting effects of angiotensin-converting enzyme inhibitor therapy on clinical. J Am Coll Cardiol. 2009. Disponível em: http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.07.008v1.
29. Rady MY, Ryan T. The effects of preoperative therapy with angiotensin-converting enzyme inhibitors on clinical outcome after cardiovascular surgery. Chest. 1998;114(2):487-94.
30. Weightman WM, Gibbs NM, Sheminant MR, Whitford EG, Mahon BD, Newman MA. Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival. Anesth Analg. 1999;88(2):286-91.